Skip to content

The Efficacy of Thai Traditional Eye Poultices for Preventing Occasional Migraine: A Clinical Study

The Efficacy of Thai Traditional Eye Poultices for Preventing Occasional Migraine

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260502010
Enrollment
24
Registered
2026-05-02
Start date
2026-07-20
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Episodic Migraine Migraine, Thai traditional medicine, Eye poultice, Migraine prevention

Interventions

A Thai traditional eye poultice will be applied to both periocular areas for 15 minutes per session, three times per week, for a total duration of 4 weeks. The poultice is prepared from herbal ingredi
Experimental Drug
Thai Traditional Eye Poultice

Sponsors

Faculty of Science and Technology, Rajamangala University of Technology Srivijaya
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Participants of either gender. 2. Individuals aged 25 to 45 years. 3. Diagnosed with episodic migraine, characterized by a headache occurring on fewer than 15 days per month, as per the International Classification of Headache Disorders, 3rd edition. 4. No documented allergy to the herbal constituents utilized in the study, namely Tinospora crispa, Centella asiatica, and Andrographis paniculata. 5. Not utilizing preventive migraine medication within the two months preceding trial participation. 6. Willing to engage in the study and capable of providing informed consent.

Exclusion criteria

Exclusion criteria: 1. Inability to participate in all designated study periods. 2. Existence of open lesions in the periocular region. 3. Existence of chronic illnesses that could influence study results or participant safety, including diabetes mellitus or hypertension. 4. Emergence of adverse reactions to the herbal poultice, including rash, pruritus, irritation, or allergic responses in the periorbital region. 5. Subsequent identification of secondary headache. 6. Notable exacerbation of headache symptoms or emergence of problems that may endanger the person. 7. Participants may voluntarily withdraw from the study at any time without compromising their entitlement to standard medical care.

Design outcomes

Primary

MeasureTime frame
Migraine impact measured using the Headache Impact Test (HIT-6) Assessed at baseline, week 2, week 3, and week 4. Headache impact measured using the Headache Impact Test (HIT-6) score.

Secondary

MeasureTime frame
Migraine-Specific Quality of Life Questionnaire (MSQ) Assessed at baseline, week 2, week 3, and week 4. Quality of life measured using the Migraine-Specific Quality of Life Questionnaire (MSQ).

Countries

Thailand

Contacts

Public ContactWasan Hayeeyahya

Faculty of Science and Technology, Rajamangala University of Technology Srivijaya

wasan.h@rmutsv.ac.th075773335

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026